When the mechanisms that replicate or repair mitochondrial DNA (mtDNA) fail, it can cause a wide range of syndromes for which ...

Researchers have discovered a type of "molecular glue" that can be used to inhibit certain pathological protein interactions.

Researchers at the University of Gothenburg have identified a small molecule, PZL-A, that restores function in the defective ...

With the discontinuation of danuglipron, Pfizer is now down to one clinical-stage obesity asset: the oral GIP analog ...

A medical breakthrough could result in the first treatment for rare but serious diseases in which genetic defects disrupt ...

Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...

A medical breakthrough could result in the first treatment for rare but serious diseases in which genetic defects disrupt cellular energy production.

A medical breakthrough could result in the first treatment for rare but serious diseases in which genetic defects disrupt cellular energy production. Researchers have identified a molecule that helps ...

Pfizer said on Monday it has discontinued development of experimental weight-loss pill danuglipron after a trial patient ...

Researchers suggest the bacteria could be designed to detect pollution or nutrients, acting as sensors to help farmers ...

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial ...